Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNAseq of U87 treated with bulk control/0.5mM 8-cpt-cAMP/1nM MS275 or a combination

ABSTRACT: RNAseq of U87 treated with bulk control/0.5mM 8-cpt-cAMP/1nM MS275 or a combination

PROVIDER: PRJNA663633 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12646327.fastq.gz	Fastqsanger.gz
	SRR12646328.fastq.gz	Fastqsanger.gz
	SRR12646329.fastq.gz	Fastqsanger.gz
	SRR12646330.fastq.gz	Fastqsanger.gz
	SRR12646331.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

RNAseq of U87 treated with bulk control/0.5mM 8-cpt-cAMP/1nM MS275 or a combination

Project description:Transcriptomics revealed that the combination of 8-cpt-cAMP and MS275 could maximize the glioma differentation compared to control or use either drug alone

2023-03-15 | GSE158015 | GEO

RNAseq of U87/over-expressed DPF3 U87 treated with bulk control/0.5mM 8-cpt-cAMP combination with 1nM MS275 for 48hrs

Project description:Transcriptomics revealed that the combination of 8-cpt-cAMP and MS275 could maximize the glioma differentation compared to control or use either drug alone

2020-09-17 | GSE158065 | GEO

RNAseq and the histone acetylated chromosome immunoprecipitation of U87 or GBM stem cells(GSC) treated with bulk control/0.5mM 8-cpt-cAMP/1nM MS275 or a combination

Project description:Transcriptomics and the ChIP-seq revealed that the combination of 8-cpt-cAMP and MS275 could maximize the glioma differentation compared to control or use either drug alone

2022-10-17 | GSE215401 | GEO

RNAseq of U87/over-expressed DPF3 U87 treated with bulk control/0.5mM 8-cpt-cAMP combination with 1nM MS275 for 48hrs

Project description:RNAseq of U87/over-expressed DPF3 U87 treated with bulk control/0.5mM 8-cpt-cAMP combination with 1nM MS275 for 48hrs

| PRJNA663874 | ENA

ChIP-seq of H3K9ac and H3K14ac in U87 glioma cells treated with differentiation agents(0.5mM 8-cpt-cAMP combined with 1nM MS275) for 48h

Project description:ChIP-seq of H3K9ac and H3K14ac in U87 glioma cells treated with differentiation agents(0.5mM 8-cpt-cAMP combined with 1nM MS275) for 48h

| PRJNA664703 | ENA

RNAseq and the histone acetylated chromosome immunoprecipitation of U87 or GBM stem cells(GSC) treated with bulk control/0.5mM 8-cpt-cAMP/1nM MS275 or a combination

Project description:RNAseq and the histone acetylated chromosome immunoprecipitation of U87 or GBM stem cells(GSC) treated with bulk control/0.5mM 8-cpt-cAMP/1nM MS275 or a combination

| PRJNA890206 | ENA

ChIP-seq of H3K9ac and H3K14ac in U87 glioma cells treated with differentiation agents(0.5mM 8-cpt-cAMP combined with 1nM MS275) for 48h

Project description:We report the diverse histone acetylation pattern on histone 3 lysine 9 and lysine14 under the cell differentiation. The genes controlled by this two histone acetylation modification can transformed the cell identity of the glioma by downregualted the promoter of oncogenes' H3K9 acetyltion and improve the promoter of neuron-differentiation related genes' H3K14 acetylation

2020-09-22 | GSE158272 | GEO

Timecourse of Gene Expression responses to cAMP in S49 Cells

Project description:Abstract Although a substantial number of hormones and drugs increase cellular cAMP levels, the global impact of cAMP and its major effector mechanism, protein kinase A (PKA), on gene expression is not known. Here we show that treatment of wild-type S49 lymphoma cells for 24 h with 8-(4-chlorophenylthio)-cAMP (CPT-cAMP), a PKA-selective cAMP analog, alters the expression of ~4500 of ~13,600 unique genes. By contrast, gene expression was unaltered in Kin– S49 cells (that lack PKA) incubated with CPT-cAMP. Changes in mRNA and protein expression of several cell-cycle regulators accompanied cAMP-induced G1-phase cell-cycle arrest of wild-type S49 cells. Within 2 h, CPT-cAMP altered expression of 152 genes that contain evolutionarily conserved cAMP-response elements (CRE) within 5 kb of transcriptional start sites, including the circadian clock gene Per1. Thus, cAMP through its activation of PKA produces extensive transcriptional regulation in eukaryotic cells. These transcriptional networks include a primary group of CRE-containing genes and secondary networks that include the circadian clock. Keywords: time-course

2005-04-15 | GSE2413 | GEO

Transcription profiling of mouse S49 cells to study the global impact of cAMP and protein kinase A on gene expression

Project description:Although a substantial number of hormones and drugs increase cellular cAMP levels, the global impact of cAMP and its major effector mechanism, protein kinase A (PKA), on gene expression is not known. Here we show that treatment of wild-type S49 lymphoma cells for 24 h with 8-(4-chlorophenylthio)-cAMP (CPT-cAMP), a PKA-selective cAMP analog, alters the expression of ~4500 of ~13,600 unique genes. By contrast, gene expression was unaltered in Kin- S49 cells (that lack PKA) incubated with CPT-cAMP. Changes in mRNA and protein expression of several cell-cycle regulators accompanied cAMP-induced G1-phase cell-cycle arrest of wild-type S49 cells. Within 2 h, CPT-cAMP altered expression of 152 genes that contain evolutionarily conserved cAMP-response elements (CRE) within 5 kb of transcriptional start sites, including the circadian clock gene Per1. Thus, cAMP through its activation of PKA produces extensive transcriptional regulation in eukaryotic cells. These transcriptional networks include a primary group of CRE-containing genes and secondary networks that include the circadian clock.

2007-08-31 | E-GEOD-2413 | biostudies-arrayexpress

RNA-seq Analysis of U87: Ctrl, U87:EGFR, U87:EGFRvIII, U87:EGFR+EGFRvIII and U87:EGFR+EGFRvIII KRAS KO

Project description:RNA-seq Analysis of U87: Ctrl, U87:EGFR, U87:EGFRvIII, U87:EGFR+EGFRvIII and U87:EGFR+EGFRvIII KRAS KO

| PRJNA483397 | ENA